Differentiating Between JAK/TYK2 Inhibition in Psoriasis
English
Recorded Courses
hosted by Paradigm Medical Communications, LLC
hosted by Paradigm Medical Communications, LLC
attend it anywhere online
category
Healthcare Management, Medicine, Nursing
Nurse Practitioners, Dermatology
price
Free
Differentiating Between JAK/TYK2 Inhibition in Psoriasis is organized by Paradigm Medical Communications, LLC.,Release Date: August 9, 2022,Expiration Date: December 16, 2023,Program Overview:,Psoriasis is a common autoimmune disorder with associated comorbidities that are more than skin deep. Patients with psoriasis are at increased risk for cardiovascular and metabolic disease, malignancies, and anxiety/depression. This activity will provide clinicians with a solid foundation for understanding the pathophysiology of psoriasis along with other autoimmune diseases, how this pathophysiology informs treatment options, and the most recent clinical trial data for current and emerging agents and management recommendations available to guide therapy selection.,Learning Objectives:,Upon completion of this activity, participants should be able to:,• Describe how inhibiting the Janus kinase (JAK)/tyrosine kinase 2 (TYK2)-signal transducer and activator of transcription (STAT) pathway is effective in multiple autoimmune diseases.